Insulin remains one of the most important treatments for people living with diabetes. Whether someone has Type 1 diabetes or advanced Type 2 diabetes, insulin therapy helps control blood sugar levels, ...
The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. U.S. regulators took action Wednesday that ...
A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...
More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...
March 11, 2011 — Insulin degludec (Novo Nordisk), a novel, ultra-long-acting basal formulation, provides comparable glycemic control to insulin glargine without additional adverse events and may ...
Hosted on MSN
What Is NPH Insulin?
NPH insulin is an older type of synthetic insulin that helps people with diabetes control their blood sugar. It’s typically injected once or twice a day at regular times and is designed to deliver a ...
LEHI, Utah, Oct. 16, 2025 /PRNewswire/ -- Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results